{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:54:24Z","timestamp":1790744064320,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and have recently emerged as potential therapeutic targets. In this comprehensive review, we summarize the latest findings on the roles of CAFs in various hematologic malignancies, including acute leukemia, multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms, and lymphoma. We also explore their involvement in tumor progression, drug resistance, and the various signaling pathways implicated in their activation and function. While the underlying mechanisms and the existence of multiple CAF subtypes pose challenges, targeting CAFs and their associated pathways offers a promising avenue for the development of innovative treatments to improve patient outcomes in hematologic malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1193978","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:31:07Z","timestamp":1694017867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziyang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176091","volume-title":"Drug resistance in hematological Malignancies","author":"Auberger","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2013.12.009","article-title":"Carcinoma-associated fibroblasts provide operational flexibility in metastasis","volume-title":"Seminars in cancer biology","author":"De Wever","year":"2014"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.03.001","article-title":"Targeting CAFs to overcome anticancer therapeutic resistance","volume":"8","author":"Saw","year":"2022","journal-title":"Trends Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.353","article-title":"Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells","volume":"36","author":"Richards","year":"2017","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.015","article-title":"Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin \u03b23\u2013p38 MAPK signalling","volume":"442","author":"Wen","year":"2019","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01367-x","article-title":"Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients","volume":"20","author":"Herrera","year":"2021","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7150\/thno.60540","article-title":"Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31792","article-title":"Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1097","article-title":"Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for Clcf1 and Il-6 in non\u2013small cell lung cancer in vivo","volume":"72","author":"Vicent","year":"2012","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.44.6.326","article-title":"Acute leukemia in adults: recent developments in diagnosis and treatment","volume":"44","author":"Devine","year":"1994","journal-title":"CA: Cancer J Clin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-016-0405-0","article-title":"Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells","volume":"35","author":"Zhai","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"110610","DOI":"10.1016\/j.biopha.2020.110610","article-title":"Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia","volume":"130","author":"Pan","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2008.07130.x","article-title":"TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells","volume":"142","author":"Xu","year":"2008","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e26414","DOI":"10.1002\/pbc.26414","article-title":"A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators\u2019 Consortium study (POE 10-03)","volume":"64","author":"Cooper","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-01870-7","article-title":"Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts","volume":"21","author":"Li","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell\u2013derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.254","article-title":"Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies","volume":"28","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3183-y","article-title":"u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression","volume":"17","author":"Ciavarella","year":"2017","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2499","article-title":"A lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma","volume":"35","author":"Kanehira","year":"2017","journal-title":"Stem Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J Natl Cancer Institute"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.289","article-title":"Halting pro-survival autophagy by TGF\u03b2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients","volume":"30","author":"Frassanito","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.18632\/oncotarget.2661","article-title":"Cancer associated fibroblasts in hematological Malignancies","volume":"6","author":"Raffaghello","year":"2015","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvaa064","article-title":"Exosomes derived from chronic lymphocytic leukaemia cells transfer miR-146a to induce the transition of mesenchymal stromal cells into cancer-associated fibroblasts","volume":"168","author":"Yang","year":"2020","journal-title":"J Biochem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/347270","article-title":"The hematopoietic niche in myeloproliferative neoplasms","volume":"2015","author":"Schmitt-Graeff","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2015.05.004","article-title":"Expression of \u03b1-smooth muscle actin determines the fate of mesenchymal stromal cells","volume":"4","author":"Talele","year":"2015","journal-title":"Stem Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5207.5207","volume-title":"LOXL2 highly-expressed induce the transition of stromal cells into cancer-associated fibroblasts which maybe involve in myeloproliferative neoplasms progession","author":"Xu","year":"2015"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5495.5495","volume-title":"Emerging potential roles of lysyl-oxidase-like 2 stimulates cancer associated fibroblasts promoting myelofibrosis of myeloproliferative neoplasms","author":"Liu","year":"2016"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14501","article-title":"A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Br J haematology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"25055","DOI":"10.18632\/aging.203779","article-title":"IGFBP-6\/sonic hedgehog\/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis","volume":"13","author":"Longhitano","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Primary Care: Clinics Office Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"H\u00f6pken","year":"2019","journal-title":"Trends Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1182\/blood.V128.22.3019.3019","article-title":"Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism","volume":"128","author":"Aoki","year":"2016","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1038\/s41388-021-01829-y","article-title":"Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in Malignant lymphoma","volume":"40","author":"Kunou","year":"2021","journal-title":"Oncogene"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13873","article-title":"Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells","volume":"110","author":"Sakamoto","year":"2019","journal-title":"Cancer Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1182\/blood-2018-99-116409","article-title":"Diffuse large B-cell lymphoma remodels the fibroblastic reticular network that acquires aberrant immunosuppressive capabilities; implications for the regulation of anti-tumor immunity in the immuno-oncology era","volume":"132","author":"Apollonio","year":"2018","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood.v126.23.1474.1474","article-title":"Diffuse large B-cell lymphoma (DLBCL) tumor cells reprogram lymphatic fibroblasts into cancer-associated fibroblasts (CAFs) that contribute to tumor microenvironment (TME)-driven immune privilege","volume":"126","author":"Apollonio","year":"2015","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.856363","article-title":"Deconvolution of adult T-cell leukemia\/lymphoma with single-cell RNA-seq using frozen archived skin tissue reveals new subset of cancer-associated fibroblast","volume":"13","author":"Joo","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163906","article-title":"Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy","volume":"14","author":"Glabman","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2020.0042","article-title":"Broadening drug design and targets to tumor microenvironment? Cancer-associated fibroblast marker expression in cancers and relevance for survival outcomes","volume":"24","author":"Dzobo","year":"2020","journal-title":"OMICS"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2020.0019","article-title":"Taking a full snapshot of cancer biology: deciphering the tumor microenvironment for effective cancer therapy in the oncology clinic","volume":"24","author":"Dzobo","year":"2020","journal-title":"OMICS"},{"key":"B51","doi-asserted-by":"publisher","first-page":"114504","DOI":"10.1016\/j.addr.2022.114504","article-title":"Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting","volume":"189","author":"Rimal","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020376","article-title":"The tumor microenvironment in tumorigenesis and therapy resistance revisited","volume":"15","author":"Dzobo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1022979","article-title":"Cancer-associated fibroblasts in acute leukemia","volume":"12","author":"Gu","year":"2022","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2020.0023","article-title":"Architecture of cancer-associated fibroblasts in tumor microenvironment: mapping their origins, heterogeneity, and role in cancer therapy resistance","volume":"24","author":"Dzobo","year":"2020","journal-title":"OMICS"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1193978\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:31:16Z","timestamp":1694017876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1193978\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":56,"alternative-id":["10.3389\/fonc.2023.1193978"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1193978","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"article-number":"1193978"}}